Skip to main content

Patient Recruitment

Nivolumab for Patients with IDH-Mutant Gliomas

A Study for Adults With Recurrent IDH1 or IDH2 Mutated Gliomas

doctor and patient reviewing MRI results

National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.

What the study involves:

  • Full physical and neurological examination
  • Health and symptoms questionnaire
  • MRIs and laboratory tests
  • Study of tumor tissue from prior surgeries
  • Receive drug nivolumab for up to 20 treatments over 64 weeks
  • Your samples used for genetic and biomarker testing
  • Monitoring calls every six months after treatment
  • Visits every month during treatment and 28, 60, 100 days after treatment
  • All tests, procedures and medications provided at no cost

You can participate if you:

  • Are age 18 or older
  • Are diagnosed with a glioma with IDH1or IDH2 mutation that has returned
  • Do not have hepatitis
  • Are not pregnant or breastfeeding

The NIH Clinical Center, America's Research Hospital located in Bethesda, MD Metro red line (Medical Center stop).

For more information:
NIH Clinical Center
Office of Patient Recruitment
800-411-1222 (refer to study 19-C-0006)
800-877-8339 TTY/ASCII
Se habla español

Or go online:

Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

NOTE: PDF documents require the free Adobe Reader.

This page last updated on 10/22/2021

You are now leaving the NIH Clinical Center website.

This external link is provided for your convenience to offer additional information. The NIH Clinical Center is not responsible for the availability, content or accuracy of this external site.

The NIH Clinical Center does not endorse, authorize or guarantee the sponsors, information, products or services described or offered at this external site. You will be subject to the destination site’s privacy policy if you follow this link.

More information about the NIH Clinical Center Privacy and Disclaimer policy is available at